Efforts To Adopt Path-Breaking Pharmaceutical Global Trade Rules In TPP Remains Work-In-Progress
This article was originally published in PharmAsia News
Executive Summary
Efforts to get a major new trade bloc to adopt stronger pharmaceutical intellectual property rules, including a potential path breaking agreement on biologics data exclusivity remains a work-in-progress, trade negotiators said at the end of the 18th round of the Trans-Pacific Partnership talks. But hope still floats the diverse group of 12 countries might find compromise language.
You may also be interested in...
Drug Reimbursement, Biologics Exclusivity Should Be Part Of EU Trade Talks, PhRMA And BIO Say
Branded drug industry representatives presented a number of recommendations for U.S. negotiating priorities in upcoming trade talks with the European Union at a May 30 public hearing.
Revised U.S.-Korea FTA Grants Three-year Grace Period To Korean Generic Drug Makers
SEOUL - Despite discontent among opposition parties in South Korea with the recently revised Free Trade Agreement with the U.S., Korea's generic drug makers are welcoming new supplementary agreements, which they say would give them a three-year grace period during which they could launch generic versions of patented products
List Ahead For Southeast Asia Pharma In 2015
PharmAsia News looks ahead at 2015 to highlight expected trends and events shaping the biomedical community in Southeast Asia.